Drug target | Drug name | Study participants | Main Results | References |
---|---|---|---|---|
GLP-1R agonists | dulaglutide | 64 adults with T2DM and more than 6.0% LFC by MRI-PDFF | Reduce absolute LFC by 3.5% and liver enzyme after 24 weeks | [97] |
Exenatide | 76 overweight/obese patients with T2DM and LFC by MRS ≥ 10.0% | Reduce LFC by 17.55U/L and fibrosis 4 score by 0.10 after 24-week treatment | [98] | |
Liraglutide | 52 overweight patients with NASH proved by biopsy | Achieve resolution in 39% participants and reduce progression of fibrosis (9% vs 36% in the control group) after 48 weeks | [99] | |
Semaglutide | 320 patients with NASH and liver fibrosis (F1-F3) proved by biopsy | Achieve NASH resolution without worsening fibrosis in 36–59% participants after 72-week intervention. Improve liver fibrosis in 43% participants in the 0.4-mg group | [100] | |
GLP-1R/GIP co-agonist | Tirzepatide | 296 overweight/obese participants with T2DM and fatty liver index of at least 60 | Reduce absolute MRI-PDFF LFC by 8.09% after 52-week intervention | [108] |
316 patients with type 2 diabetes with or without stable metformin therapy | Reduce ALT, AST, keratin-18 and procollagen III after 26 weeks | [109] |